Sign up online today & collaborate
or click here to find out more
Listed drug developer Redx Pharma has unveiled plans to relocate its head office from Liverpool to Alderley Park.
The company has outlined plans to create a 74,000 sq ft drug development facility that brings together its three subsidiaries onto a single site.
It has reached an agreement with science park operator Manchester Science Partnerships that will see Alderley Park become the new home for Redx Oncology. The business develops anti-cancer drugs and is currently based within the Royal Liverpool Hospital's Duncan Building, which is due to be demolished in 2017.
Redx already has two other subsidiaries, Redx Anti-Infectives and Redx Immunology, based at Alderley Park in 37,000 sq ft of laboratory and office space.
The Redx Pharma move is expected to complete by the end of 2016. The group's 88 Liverpool-based jobs will relocate, meaning that all 193 Redx staff will operate on the same site for the first time.
Murray said: "We've looked very hard to find alternative options in Liverpool but simply put there weren't any options that were suitable.
"We weren't able to find a facility that could support the operations we have in cancer. We do a lot of chemistry and there were specific things that we couldn't find in Liverpool."
In March 2013, AstraZeneca announced a planned investment of about £330m in a purpose-built R&D centre and corporate HQ in Cambridge alongside proposals to end R&D at its Alderley Park complex, which had approximately 2,900 employees at the time. The company, which planned to remain a tenant at Alderley Park with approximately 700 staff in non-R&D roles, estimated that around 1,600 roles would relocate from the site over a three-year period.
Since then, Alderley Park has been repositioned as a hub for a variety of bioscience and life science businesses.
Murray said: "Alderley Park is a truly world-class facility so it makes sense to do this. It's not about being a Liverpool company or an Alderley Park one. We're a company based in the North West of England. We've been on two sites for the past three years and we'll continue to work closely with our partners across the region.
"The infrastructure at Alderley Park is properly world class and there's a great community in terms of the number of related companies that are there. I think Alderley Park has got a great future and it's a real opportunity. It's a blank sheet of paper to create a real bioscience hub in the North and we're really excited to be a part of it."
Redx Pharma completed an initial public offering on AIM in March 2015 with a market capitalisation of £55.2m.
Dr Chris Doherty, site director at Alderley Park, said: "The decision to locate their oncology division here and make Alderley Park their new headquarters marks a significant milestone in the history of the park.
"Redx exemplifies the world-class companies and skills that are moving to Alderley Park. It will truly be a bioscience cluster for the future and we are delighted that Redx will be a part of it."